vs
Side-by-side financial comparison of Adaptive Biotechnologies Corp (ADPT) and MakeMyTrip Ltd (MMYT). Click either name above to swap in a different company.
MakeMyTrip Ltd is the larger business by last-quarter revenue ($88.6M vs $70.9M, roughly 1.2× Adaptive Biotechnologies Corp). On growth, Adaptive Biotechnologies Corp posted the faster year-over-year revenue change (35.1% vs 11.8%).
ExpreS2ion Biotechnologies is a Danish biotechnology company specialised in the development of new vaccines and immunotherapy products based in Hørsholm, Denmark and listed on the Nasdaq First North Growth Market Sweden.
MakeMyTrip Limited is an Indian online travel company, headquartered in Gurgaon. Founded in 2000, it operates an online travel-booking platform for travel services such as airline tickets, hotel reservations, holiday packages, and rail and bus tickets. The company also maintains offices outside India, including locations in New York, Singapore, Kuala Lumpur, Phuket, Bangkok, Dubai and Istanbul.
ADPT vs MMYT — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2022
| Metric | | |
|---|---|---|
| Revenue | $70.9M | $88.6M |
| Net Profit | $3.4M | — |
| Gross Margin | 73.6% | — |
| Operating Margin | -27.1% | 3.8% |
| Net Margin | 4.7% | — |
| Revenue YoY | 35.1% | 11.8% |
| Net Profit YoY | — | — |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $70.9M | — | ||
| Q4 25 | $71.7M | — | ||
| Q3 25 | $94.0M | — | ||
| Q2 25 | $58.9M | — | ||
| Q1 25 | $52.4M | — | ||
| Q4 24 | $47.5M | — | ||
| Q3 24 | $46.4M | — | ||
| Q2 24 | $43.2M | — |
| Q1 26 | $3.4M | — | ||
| Q4 25 | $-13.6M | — | ||
| Q3 25 | $9.5M | — | ||
| Q2 25 | $-25.6M | — | ||
| Q1 25 | $-29.9M | — | ||
| Q4 24 | $-33.7M | — | ||
| Q3 24 | $-32.1M | — | ||
| Q2 24 | $-46.2M | — |
| Q1 26 | 73.6% | — | ||
| Q4 25 | 74.6% | — | ||
| Q3 25 | 80.7% | — | ||
| Q2 25 | 69.4% | — | ||
| Q1 25 | 67.6% | — | ||
| Q4 24 | 62.0% | — | ||
| Q3 24 | 64.1% | — | ||
| Q2 24 | 55.3% | — |
| Q1 26 | -27.1% | — | ||
| Q4 25 | -17.8% | — | ||
| Q3 25 | 10.9% | — | ||
| Q2 25 | -42.5% | — | ||
| Q1 25 | -56.4% | — | ||
| Q4 24 | -71.3% | — | ||
| Q3 24 | -70.3% | — | ||
| Q2 24 | -109.6% | — |
| Q1 26 | 4.7% | — | ||
| Q4 25 | -18.9% | — | ||
| Q3 25 | 10.2% | — | ||
| Q2 25 | -43.5% | — | ||
| Q1 25 | -56.9% | — | ||
| Q4 24 | -71.0% | — | ||
| Q3 24 | -69.1% | — | ||
| Q2 24 | -107.0% | — |
| Q1 26 | — | — | ||
| Q4 25 | $-0.08 | — | ||
| Q3 25 | $0.06 | — | ||
| Q2 25 | $-0.17 | — | ||
| Q1 25 | $-0.20 | — | ||
| Q4 24 | $-0.22 | — | ||
| Q3 24 | $-0.22 | — | ||
| Q2 24 | $-0.31 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $77.6M | $213.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $896.5M |
| Total Assets | $505.9M | $1.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $77.6M | — | ||
| Q4 25 | $70.5M | — | ||
| Q3 25 | $55.0M | — | ||
| Q2 25 | $43.2M | — | ||
| Q1 25 | $50.6M | — | ||
| Q4 24 | $47.9M | — | ||
| Q3 24 | $38.1M | — | ||
| Q2 24 | $59.8M | — |
| Q1 26 | — | — | ||
| Q4 25 | $218.8M | — | ||
| Q3 25 | $204.4M | — | ||
| Q2 25 | $179.7M | — | ||
| Q1 25 | $190.4M | — | ||
| Q4 24 | $202.7M | — | ||
| Q3 24 | $223.8M | — | ||
| Q2 24 | $241.6M | — |
| Q1 26 | $505.9M | — | ||
| Q4 25 | $512.7M | — | ||
| Q3 25 | $490.6M | — | ||
| Q2 25 | $496.6M | — | ||
| Q1 25 | $510.9M | — | ||
| Q4 24 | $539.4M | — | ||
| Q3 24 | $558.5M | — | ||
| Q2 24 | $584.9M | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
